OMNIX MEDICAL: UN PAPILLON CONTRE ACINETOBACTER BAUMANNII
Une nouvelle technologie inspirée par la nature pour éradiquer de dangereuses bactéries multirésistantes. (A new technology inspired by nature to eradicate dangerous multiresistant bacteria.)
COMPANY NEWS: OMNIX MEDICAL WINS €10.8M IN EIC ACCELERATOR FUNDING
Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has been awarded €10.8 million in EU funding under the EIC Accelerator Programme.
OMNIX MEDICAL ANNOUNCES SUCCESSFUL $8.5 MILLION FUNDING ROUND
Omnix Medical, a Jerusalem-based biopharmaceutical company, has completed an $8.5 million round led by Tal Capital (US) and Entrée Capital (IL) in association with UK based businessman Vincent Chenkwiz of CBG Group (UK) and joined by Xenia Ventures (IL) VLX Ventures (IL) and the Israeli Innovation Authority (IIA). Since its inception, the company has raised $10M.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).